MedMira posts FY2025 Q4 & Year‑End Results, sees product approvals and ongoing losses

MedMira Inc. (TSXV:MIR) has released its financial results for the fiscal year ending July 31, 2025 — and while the biotech firm made progress on regulatory and product fronts, it also posted a significantly larger loss compared with the prior year. 📈 Business Highlights In FY2025, MedMira rolled out its newly approved Multiplo® Rapid TP/HIV Test and the latest generation of Reveal® Rapid HIV Test in Canada. Following the fiscal year, MedMira gained approval from Health Canada for its Reveal® TP (Syphilis) rapid test — the fastest syphilis antibody test available nationwide. Provincial‑level validations are complete, and deployments via provincial buying groups have begun — marking a key phase in scaling distribution to Canadian health‑care providers. In the U.S., MedMira secured listings with the U.S. Department of Veterans Affairs and other federal buyers, strengthening its positioning to bid for multi‑year contracts using its FDA‑approved Reveal® G4 HIV-1/2 rapid test. 💵 Financial Performance (FY2025 vs FY2024) MetricFY2025FY2024Revenue (sales & services)US$ 240,509US$ 412,568 Gross profitUS$ 172,851US$ 226,489 Gross margin≈ 72%≈ 55% Operating expensesUS$ 3,762,598US$ 2,799,485 Net lossUS$ 4,524,407US$ 3,326,321 Working capital deficitIncreased to US$ 3,141,511 (18% higher vs prior year) The numbers reveal a sharp drop in revenue — nearly 42% down — although gross margin improved. Still, rising expenses tied to research, development, and commercialization drove a steeper net loss. 🔭 What’s Next MedMira isn’t pausing: the company has started the second phase of clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test, with results due in Q1 2026. It is also pushing forward commercialization of its M i RO Q diagnostic platform — which builds on its core RVF technology — aiming to bring faster, AI‑assisted diagnostics (potentially in oncology) to market sooner. Even with the financial headwinds, these regulatory wins and product developments could pave the way for broader market penetration and — down the line — a turnaround in financial performance. #MedMira #Biotech #RapidTesting #HealthcareDiagnostics #SlimScan #GrowthStocks #CANSLIM